Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $27.00 price target on Spero Therapeutics (NASDAQ: SPRO), saying the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE